Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

Plain-language summary

This study explores new molecular targets in the brain tumor medulloblastoma and investigates CDK4/6 inhibitor drugs (Palbociclib, Ribociclib, Abemaciclib). It enrolls patients who were operated on for medulloblastoma during childhood. It is in Early Phase 1 and is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Early Phase 1

Status

Recruiting

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Intervention

CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)

Start date

11/25/2024

Estimated completion

8/31/2026

Countries

Italy

Related genes

Locations

• Roma, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* All patients affected by Medulloblastoma operated on at the Pediatric Neurosurgery Unit during their pediatric age will be elected to take part to the study